Utilization Impacts of New Oral Substitutes for Parenteral Cancer-Related Therapies

Amy J. Davidoff, PhD; Amer Zeidan, MD; Franklin Hendrick, BS; Bruce C. Stuart, PhD; Vu H. Duong, MD, MS; Maria R. Baer, MD; Rahul A. Shenolikar, PhD; and Steven D. Gore, MD ABSTRACT Background: Iron chelation therapy is indicated in myelodysplastic syndrome patients with transfusion-related iron overload. Deferoxamine, administered by lengthy subcutaneous infusions 5 to 7 days per week, was FDAapproved in 1968, whereas the oral chelator deferasirox was approved in November 2005.

http://ift.tt/1GjxHjB